Kala Pharmaceuticals, Inc. (KALA): Price and Financial Metrics
KALA Stock Summary
- Kala Pharmaceuticals Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 11.49% of US listed stocks.
- KALA's price/sales ratio is 73.82; that's higher than the P/S ratio of 95.62% of US stocks.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for KALA comes in at -34.2% -- higher than that of only 7.68% of stocks in our set.
- Stocks that are quantitatively similar to KALA, based on their financial statements, market capitalization, and price volatility, are QUOT, XENT, ECOR, DADA, and BIOL.
- Visit KALA's SEC page to see the company's official filings. To visit the company's web site, go to www.kalarx.com.
KALA Stock Price Chart Interactive Chart >
KALA Price/Volume Stats
|Current price||$7.66||52-week high||$14.68|
|Prev. close||$7.63||52-week low||$6.00|
|Day high||$7.88||Avg. volume||2,244,436|
|50-day MA||$7.68||Dividend yield||N/A|
|200-day MA||$8.07||Market Cap||471.49M|
Kala Pharmaceuticals, Inc. (KALA) Company Bio
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles technology. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is based in Waltham, Massachusetts.
KALA Latest News Stream
|Loading, please wait...|
KALA Latest Social Stream
View Full KALA Social Stream
Latest KALA News From Around the Web
Below are the latest news stories about Kala Pharmaceuticals Inc that investors may wish to consider to help them evaluate KALA as an investment opportunity.
According to JPMorgan CEO Jamie Dimon, the US is on the cusp of an economic boom which should fuel growth at least until 2023. Dimon attributes the prospect of strong growth to several reasons. “I have little doubt that with excess savings, new stimulus savings, huge deficit spending, more QE, a new potential infrastructure bill, a successful vaccine and euphoria around the end of the pandemic, the U.S. economy will likely boom,” Dimon recently said.
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that Cigna has added EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% as a preferred brand on its commercial formulary, effective May 15, 2021.
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that management will participate in the following virtual healthcare investor conferences in March.
Kala Pharmaceuticals Is it time to Buy before this week’s earning report Stock market Insights & financial analysis
Kala Pharmaceuticals announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
KALA Price Returns
Continue Researching KALAWant to see what other sources are saying about Kala Pharmaceuticals Inc's financials and stock price? Try the links below:
Kala Pharmaceuticals Inc (KALA) Stock Price | Nasdaq
Kala Pharmaceuticals Inc (KALA) Stock Quote, History and News - Yahoo Finance
Kala Pharmaceuticals Inc (KALA) Stock Price and Basic Information | MarketWatch